Literature DB >> 30776053

Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.

Alvaro San-Juan-Rodriguez1, Max V Prokopovich1,2, William H Shrank2, Chester B Good2, Inmaculada Hernandez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30776053      PMCID： PMC6503568          DOI： 10.1001/jamainternmed.2018.7656

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.

Authors:  Natalie McCormick; Zachary S Wallace; Chana A Sacks; John Hsu; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2020-01-06       Impact factor: 10.995

2.  Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.

Authors:  Inmaculada Hernandez; Chester B Good; William H Shrank; Walid F Gellad
Journal:  JAMA       Date:  2019-04-23       Impact factor: 56.272

3.  Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.

Authors:  Sarina C Lowe; Jenny S Sauk; Berkeley N Limketkai; Mary R Kwaan
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

4.  Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.

Authors:  Alvaro San-Juan-Rodriguez; Vincent M Piro; Chester B Good; Walid F Gellad; Inmaculada Hernandez
Journal:  J Manag Care Spec Pharm       Date:  2021-01

5.  Competition and price among brand-name drugs in the same class: A systematic review of the evidence.

Authors:  Ameet Sarpatwari; Jonathan DiBello; Marie Zakarian; Mehdi Najafzadeh; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2019-07-30       Impact factor: 11.069
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.